SMARCB1 and rhabdoid tumor: Tazemetostat was recently evaluated for the treatment of pediatric tumors (primarily rhabdoid tumors) with EZH2 mutation or loss of the SWI/SNF subunits SMARCB1 or SMARCA4 (17).